Business Context and Reporting Period
This Form 8-K is a current report filed by Keros Therapeutics, Inc. on February 7, 2023. The filing serves as a Regulation FD disclosure to announce an upcoming corporate presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is informational regarding a corporate event and does not contain financial statements or performance data.
Material Changes
No material financial changes or operational updates are reported in this document. The sole material event is the scheduling of a management presentation.
Guidance, Outlook, and Management Commentary
- Upcoming Presentation: Jasbir Seehra, President and Chief Executive Officer, is scheduled to present at the SVB Securities Global Biopharma Conference.
- Date and Time: Tuesday, February 14, 2023, at 3:40 p.m. Eastern time.
- Legal Disclaimer: The information in this report and the accompanying press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the SVB Securities Global Biopharma Conference presentation (February 14, 2023, 3:40 p.m. ET).
- Review the full text of the press release attached as Exhibit 99.1 for any additional details on the presentation topic.
- Confirm that no financial data is included in this specific 8-K filing; refer to the most recent 10-K or 10-Q for financial metrics.